Tirzepatide week by week

Reviewed 9 sourcesPublished by PepVault

What to expect on tirzepatide week by week: the label's dose steps, when appetite and nausea change, weight loss from week 20 to year 3, and the plateau.

A smiling silver-haired man in a sleeveless training top in his garage gym, a towel over his shoulder and a water bottle in his hand
Model. Individual results vary.
Last reviewed
Sources
9
Questions
7
Compounds
1

The short answer

Tirzepatide is a once-weekly injection that acts on two gut-hormone receptors, GIP and GLP-1. The label starts at 2.5 mg for four weeks, then steps up 2.5 mg at a time, at least four weeks apart, to 5, 10 or 15 mg. Nausea clusters around the step-ups, and weight keeps falling for months: 15 to 21% at 72 weeks on 5 to 15 mg in SURMOUNT-1, against 3% on placebo.

PepVault research · Last reviewed · 9 sources

Evidence: Randomised phase 3 trials in people (SURMOUNT-1 and -4, and the open-label SURMOUNT-5, in NEJM and JAMA), a post hoc analysis of two of them, and the FDA labels for Zepbound and Mounjaro; tirzepatide is FDA-approved, and some mechanism details come from cell and mouse studies.

How does tirzepatide work?

Tirzepatide is one peptide that switches on two receptors, GIP and GLP-1, the targets of two hormones the gut releases after a meal15. GLP-1 is one of the body's own regulators of appetite and of how much is eaten; tirzepatide cuts calorie intake, which the label puts down to its effect on appetite, and it slows the stomach1. Both receptors sit in the brain areas that set appetite, and in animal studies tirzepatide reaches those areas and switches on their neurons1. In mice, it cut food intake and body weight more than a GLP-1 drug alone5.

The stomach-slowing is strongest after the very first dose and fades over time1. The label also notes that the weight lost is more fat than lean mass1.

It lasts. A 20-carbon fatty acid fixed to the peptide lets it ride on albumin, a protein in the blood, which stretches its half-life to about five days (five to six in people with obesity), so one dose a week is enough12. The level builds with each weekly dose and reaches a steady state after four weeks1. Because exposure rises in proportion to the dose1, each new step takes about the same month to settle. The chart shows that build-up.

Try it

How Tirzepatide builds up

An estimate from a half-life of about 5 days, one dose a week for four weeks. The shape of the level, not a measurement.

Try your own scheduleTirzepatide in the library

A smiling woman in a blue top leaning on her kitchen counter with her phone and a notebook

Model. Individual results vary.

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What doses does the label use, and how fast do they climb?

Zepbound, the weight-management brand, starts at 2.5 mg once a week for four weeks. That first dose is for starting only: the label does not approve it as a maintenance dose. Then it goes to 5 mg, and from there it can rise 2.5 mg at a time, with at least four weeks on each dose, to a maintenance dose of 5, 10 or 15 mg for weight (10 or 15 mg for sleep apnoea). 15 mg is the maximum1. Mounjaro, the type 2 diabetes brand, uses the same 2.5 mg start and 2.5 mg steps, at least four weeks apart, when more glucose control is needed, up to 15 mg in adults2. The label sets this slow climb to lower the risk of stomach side effects1.

SURMOUNT-1, the main obesity trial, climbed the same way: up 2.5 mg every four weeks until each group reached its assigned 5, 10 or 15 mg, with the whole escalation finished by week 2034. If a weekly dose is missed, the label's rule is to take it within four days; after more than four days, skip it and go back to the usual day1.

These are the label's and the trials' schedules. A prescriber chooses the maintenance dose by weighing response and tolerability, and can settle on a lower one if a maintenance dose is not tolerated1. They describe what was approved and studied, not a dose for any one person.

What happens week by week?

The table follows the full climb to 15 mg at the label's fastest pace, four weeks a step1, as SURMOUNT-1's 15 mg group did4, and lines it up with what the trials measured. Weight loss is the average change from starting weight; in SURMOUNT-1, people started at about 105 kg on average3.

WeeksLabel dose stepWhat the trials show
1–42.5 mgThe starting dose. The drug level reaches its steady state after four weekly doses1.
5–85 mgThe first step-up, and the lowest maintenance dose. The SURMOUNT-1 5 mg group stays here4.
9–127.5 mgThe second step-up4.
13–1610 mgThe third step-up. The 10 mg group reaches its final dose4.
17–2012.5 mgThe fourth step-up. By week 20, people in the 10 and 15 mg groups who were still taking it were down 13.2 kg on average, against 2.5 kg on placebo4.
21 onward15 mgThe last step-up: the 15 mg group reaches the maximum dose34.
Weeks 24–36MaintenanceAmong people who stayed on treatment and lost at least 5%, half had reached their plateau by about week 24 to 36, depending on starting BMI6.
Week 36MaintenanceSURMOUNT-4: people who finished a 36-week run-in on their highest tolerated dose, 10 or 15 mg, were down 20.9%7.
Week 72MaintenanceSURMOUNT-1: down 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo3. Counting only data from while people stayed on the drug (the efficacy estimand): 16.0%, 21.4% and 22.5%, against 2.4%4.
Week 88MaintenanceSURMOUNT-4: down 25.3% in all for people who kept taking it, against 9.9% for those switched to placebo at week 367.
Week 176MaintenanceIn the SURMOUNT-1 participants who also had prediabetes, treated for three years: down 12.3%, 18.7% and 19.7%, against 1.3% on placebo8.

The shape is in those numbers: about 13 kg gone by the end of the dose climb in the 10 and 15 mg groups, and the loss still building well after the last step. By week 72, 50% of people on 10 mg and 57% on 15 mg had lost at least 20% of their weight, against 3% on placebo3.

When does appetite change?

Early, by most accounts. The weight trials here measured weight rather than hunger, so the clearest picture of appetite comes from the people taking it. What the label does show is that the stomach-slowing is at its strongest right after the first dose1.

Commonly reported: appetite dropping within days of the first dose; very strong appetite suppression, with meals ending early and 'food noise' going quiet; and nausea or tiredness for a day or two after the injection, mostly after a dose increase.

What side effects come, and when?

The common ones are stomach effects, and they follow the dose steps. In SURMOUNT-1 most were mild to moderate and came mainly during dose escalation3, and the label states that most nausea, vomiting and diarrhoea came during the step-ups and eased over time1. In the label's pool of two weight trials (SURMOUNT-1, and a second in people with type 2 diabetes that had no 5 mg group), on 5, 10 and 15 mg1:

  • Nausea: 25%, 29% and 28%, against 8% on placebo.
  • Diarrhoea: 19%, 21% and 23%, against 8%.
  • Constipation: 17%, 14% and 11%, against 5%.
  • Vomiting: 8%, 11% and 13%, against 2%.

Few people stopped over them: 1.9%, 3.3% and 4.3% left treatment because of stomach side effects, against 0.5% on placebo1. What helps in the step-up weeks is ordinary: smaller meals, eating slowly and stopping at the first sign of fullness, steady fluids through the day, and more fibre and water when constipation shows up.

One practical label note for those same weeks: tirzepatide can make birth-control pills less reliable, so the label advises switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after each step-up1.

When does the weight plateau, and what happens if you stop?

Weight loss during obesity treatment slows over time and eventually levels off6. A post hoc analysis of SURMOUNT-1 called it a plateau when weight changed less than 5% over 12 weeks and stayed that way. Among people who kept taking tirzepatide and lost at least 5%, the median time to plateau ran from 24 weeks for those who started overweight to 36 weeks for those with a BMI of 35 or more, and about 88 to 90% had plateaued by week 72. Higher doses, younger age and being female went with a later plateau6.

SURMOUNT-4 tested what holds the plateau. After 36 weeks on their highest tolerated dose, 10 or 15 mg, people were randomly assigned to keep going or switch to placebo. Over the next year, those who continued lost a further 5.5%, and 89.5% kept at least 80% of what they had lost. In those switched to placebo, weight rose 14.0%7.

Head to head, SURMOUNT-5 compared tirzepatide with semaglutide, which acts on GLP-1 alone, each at its highest tolerated dose: down 20.2% against 13.7% at 72 weeks, with stomach effects in both groups mostly mild to moderate and mostly during escalation9.

Is tirzepatide approved?

Yes. In the US it is Mounjaro for type 2 diabetes2 and Zepbound for reducing excess weight and keeping it off long term in adults with obesity, or with overweight and a weight-related condition, and for moderate to severe obstructive sleep apnoea in adults with obesity1. Both labels pair it with a reduced-calorie diet and more physical activity or exercise12.

Track it in the app

Sources

  1. Eli Lilly and Company. ZEPBOUND (tirzepatide) injection, prescribing information. DailyMed, revised August 2026. dailymed.nlm.nih.gov
  2. Eli Lilly and Company. MOUNJARO (tirzepatide) injection, prescribing information. DailyMed, 2026. dailymed.nlm.nih.gov
  3. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024
  4. ClinicalTrials.gov NCT04184622. A study of tirzepatide (LY3298176) in participants with obesity or overweight (SURMOUNT-1; sponsor Eli Lilly and Company). Results record. clinicaltrials.gov
  5. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. Mol Metab. 2018. PubMed 30473097
  6. Horn DB et al. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials. Clin Obes. 2025. PubMed 39800653
  7. Aronne LJ et al.; SURMOUNT-4 Investigators. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: the SURMOUNT-4 randomized clinical trial. JAMA. 2024. PubMed 38078870
  8. Jastreboff AM et al.; SURMOUNT-1 Investigators. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025. PubMed 39536238
  9. Aronne LJ et al.; SURMOUNT-5 Trial Investigators. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. PubMed 40353578

Newsletter · Weekly

The weekly peptide briefing.

New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.

We’ll email you a link to confirm. Your address is used for the briefing only. Privacy

PepVault for iPhone

Keep your protocol in PepVault

Log every dose, track every vial, and see your protocol come together.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo